ClinicalTrials.gg
RecruitingNCT05468554METHYRUpdated Oct 21, 2026

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

A Phase 3 interventional study of metformin and Radioactive iodine (I-131) in Thyroid Cancer, sponsored by Medical University of Bialystok. Recruiting at 2 sites in Poland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Medical University of Bialystok · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Thyroid Neoplasms with a site in Poland — 2 open to participants now, 4 under way, 2 of them phase 3. Thyroid Neoplasms · Poland.

Planned enrollment
11th of 17
160 · median 233
Started
2022
the only one that year
Phase 3
8 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Medical University of Bialystok

Among the 18 studies in Thyroid Neoplasms with a site in Poland, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2022, is one of 8 in phase 3, and was the 18th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

2 of the 18 studies in Thyroid Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Thyroid Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer

Read the detailed description

One of the most common types of endocrine cancer, especially in young women, is thyroid cancer. More than 90% of all thyroid cancers are differentiated thyroid cancers (DTC), including papillary thyroid cancer (PTC) and follicular cancer. Papillary thyroid cancer is considered as indolent tumour as progression free survival is 10 years of 98%. As per current knowledge and basing on current literature most of the PTC are considered to be low incidence of recurrence or metastasis, however, there are more invasive/aggressive types with very specific pathological and molecular characteristics. The aggressive variants of PTC were strictly associated with higher rates of extrathyroid extension, multifocality, and nodal and distant metastasis. Thyroidectomy followed by radioactive iodine 131 (131I) therapy, in higher stages of PTC disease to ablate residual thyroid cancer or treat metastases, significantly increase survival Metformin (1,1-dimethylbiguanide) is an oral antihyperglycemic drug. Orally administered metformin is absorbed into the blood in 40-60% of the drug dose. Maximum blood levels are reached after approximately 2.5 hours for the immediate-release formulation and 7 hours for the prolonged-release tablets. It is not metabolised in the liver, however, it is excreted unchanged by the kidneys, mainly through the renal tubules. Metformin is used in patients with type 2 diabetes and prediabetes as well as in insulin resistant state and in women with polycystic ovary syndrome (PCOS). Metformin works by lowering level of glucose in the blood by lowering its production by the liver and increasing the sensitivity to insulin by muscle and fat tissue. It also has a beneficial effect on serum lipids by reducing the concentration of triglycerides, total cholesterol, LDL-cholesterol and VLDL. Additionally, this drug has also several other biological effects such as anti-inflammatory, anticancer, hepatoprotective, cardioprotective, otoprotective, radioprotective and radio-sensitising.

Currently there is also a large evidential material for effectiveness of metformin therapy in re-establishing of reproductive functions and fertility in women with polycystic ovary syndrome.

Having proved the metformin restore of ovulation in PCOS and has antioxidant properties there are indications that metformin can be a therapy which will helps to maintain ovary follicle number on acceptable level. At present, there are no performed studies concerned on the evaluation of the potential beneficial effect of metformin application impact on fertility parameters in the group of women treated with 131I. Therefore, the proposed study will assess the effect of metformin intervention on the indirect parameters of fertility of women treated with 131I for papillary thyroid cancer

03

Conditions studied

  • Thyroid Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects in reproductive age >18 \<45 years.
  2. Subjects with diagnosed papillary thyroid carcinoma with various pathological stage TNM (I-II).
  3. Subjects not treated with 131I
  4. Willingness to comply with protocol procedures.

Exclusion criteria

Exclusion Criteria:

  1. to metformin.
  2. Subjects with polycystic ovarian syndrome or other diseases of the ovaries (primary / secondary ovarian failure).
  3. Subjects taking metformin during last week.
  4. Subjects with liver malfunction and abnormal hepatitis marker results ( and AST activity >3ULN.*
  5. Subjects with below 45ml/min/1.73m2.*
  6. Subjects with lactic acidosis or having history of metabolic acidosis.
  7. Subjects with serum AMH concentration* below lower range norm.
  8. Subjects with history of congestive heart disease stage III/IV.
  9. Subjects with acute myocardial ischemia (CCS 3-4).
  10. Subjects with history of sepsis or severe infection.
  11. Subject with lung disease (uncontrolled asthma based on GINA 2000 Guidelines and GOLD ≥ 3 stage).
  12. Positive result of pregnancy test or pregnancy planned during the study.
  13. Alcohol or other substance dependent syndromes.
  14. \<18.5 kg/m2.
  15. Accompanying diseases with poor prognosis in the opinion of the researcher.
  16. As per Investigator (or his designee) judgement, subject cannot participate in the study due to reasons (i.e. medical, psychiatric and/or social reason).
  17. Unreliability or lack of cooperation. *based on the laboratory results from screening visit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Metformin

    patients qualified to receive metformin and 131I treatment

    Drug: metformin · Radiation: Radioactive iodine (I-131)

  • Active comparator
    Placebo

    patients receiving placebo and 131 I treatment

    Radiation: Radioactive iodine (I-131)

  • No intervention
    Observational

    observation group, patients after thyroidectomy, characterized by low risk of cancer progression, in this case, not qualified for 131I treatment

Interventions

  • Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.

  • RadiationRadioactive iodine (I-131)

    Patients qualified to receive 131I treatment

06

What researchers measure

Primary outcomes

  1. Changes in AMH, Inhibin B and FSH levels due to the action of metformin

    The primary endpoint will be to evaluate the effect of metformin on the difference in serum AMH, inhibin B and FSH concentration and the number of antral follicles, assessed in the study groups consisted of the women with papillary thyroid cancer, treated with 131I, comparing received results during the randomized, V3, V4, V5 and V6 visits

    Time frame: 4 years

Secondary outcomes

  1. Assessment of the effect of metformin on the parameters of oxidative stress

    To evaluate the metformin modulating impact on the concentrations of selected parameters of oxidative stress assessed in the study groups consisted of the women with papillary thyroid cancer, treated with 131I, comparing received results during the randomized, V3, V4, V5 and V6 visits

    Time frame: 4 years

  2. The evaluate of difference in serum concentration of selected parameters of apoptosis

    To evaluate the effect of metformin on the difference in serum concentration of selected parameters of apoptosis between the study groups in women with papillary thyroid cancer, treated with 131I, comparing received results during the randomized, V3, V4, V5 and V6 visits

    Time frame: 4 years

  3. The evaluate of difference in expression in selected microRNA

    To evaluate the effect of metformin on the difference of expression in selected microRNA between the study groups in women with papillary thyroid cancer, treated with 131I, between the randomized visit and V3, V4, V5 and V6 visit

    Time frame: 4 years

07

Study locations

2 of 2 sites recruiting
  • Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok
    Bialystok, 15-276, Poland
    Recruiting
  • Holy Cross Cancer Center
    Kielce, Świetokrzystie 25-734, Poland
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jan 2028, 62 months after the start.

Of 19 phase 3 interventional studies under Thyroid Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 106. This study's planned 62 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Apr 2026 → Jan 2028 and completion Apr 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2022
First posted
Jul 21, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Jan 31, 2028was Apr 2026
CompletionEst.
Apr 30, 2028was Apr 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added. Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok is now Recruiting
Show site
  • Holy Cross Cancer Center · Kielce, Poland
Oct 21, 2026
Primary completion
Apr 30, 2026→Jan 31, 2028
Oct 21, 2026
Study completion
Apr 30, 2026→Apr 30, 2028
Oct 21, 2026
Eligibility
2 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedFemale subjects in reproductive age >18 <45 years.
  • EditedSubjects with diagnosed papillary thyroid carcinoma with various pathological, stage TNM (I-II).
  • RemovedSerum TSH concentration 0.1-4.9 mU/l.
Exclusion criteria
  • EditedSubjects with liver malfunction and abnormal hepatitis marker results (ALT and AST activity >3ULN.*
  • EditedSubjects with eGFR below 45ml/min/1.73m2.*
  • EditedSubjects with serum AMH concentration* below lower range norm.
  • EditedUnreliability or lack of cooperation. *based on the laboratory results from screening visit
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok · Bialystok, PolandContact added a•••@umb.edu.plContact added (no phone or email listed)
Oct 21, 2026
Sponsor
Collaborators added: Holy Cross Cancer Center in Kielce·University Clinical Hospital in Poznań·Maria Skłodowska-Curie National Research Institute of Oncology·University Clinical Hospital in Białystok
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added. Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok is now Recruiting
    Show site
    • Holy Cross Cancer Center · Kielce, Poland
    Primary completion Apr 30, 2026→Jan 31, 2028
    Study completion Apr 30, 2026→Apr 30, 2028
    Eligibility 2 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedFemale subjects in reproductive age >18 <45 years.
    • EditedSubjects with diagnosed papillary thyroid carcinoma with various pathological, stage TNM (I-II).
    • RemovedSerum TSH concentration 0.1-4.9 mU/l.
    Exclusion criteria
    • EditedSubjects with liver malfunction and abnormal hepatitis marker results (ALT and AST activity >3ULN.*
    • EditedSubjects with eGFR below 45ml/min/1.73m2.*
    • EditedSubjects with serum AMH concentration* below lower range norm.
    • EditedUnreliability or lack of cooperation. *based on the laboratory results from screening visit
    Sponsor Collaborators added: Holy Cross Cancer Center in Kielce·University Clinical Hospital in Poznań·Maria Skłodowska-Curie National Research Institute of Oncology·University Clinical Hospital in Białystok
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok · Bialystok, PolandContact added a•••@umb.edu.plContact added (no phone or email listed)
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05468554
Lead sponsor
Medical University of Bialystok
Collaborators
Medical Research Agency, Poland, Holy Cross Cancer Center in Kielce, University Clinical Hospital in Poznań, Maria Skłodowska-Curie National Research Institute of Oncology, University Clinical Hospital in Białystok
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Nov 1, 2022
Primary completion
Jan 31, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Agnieszka Adamska, Assoc.Prof.
Contact
methyr@umb.edu.pl, agnieszka.adamska@umb.edu.pl
+48 85 746 86 07
Aldona Kowalska, Assoc.Prof.
Contact
aldona.kowalska@onkol.kielce.pl
+48 41 36 74 181
Agnieszka Adamska, Assoc.Prof.
principal investigator · Medical University of Bialystok

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion